JPH0366297B2 - - Google Patents
Info
- Publication number
- JPH0366297B2 JPH0366297B2 JP20862086A JP20862086A JPH0366297B2 JP H0366297 B2 JPH0366297 B2 JP H0366297B2 JP 20862086 A JP20862086 A JP 20862086A JP 20862086 A JP20862086 A JP 20862086A JP H0366297 B2 JPH0366297 B2 JP H0366297B2
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- derivative
- carboxylic acid
- salt
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003839 salts Chemical class 0.000 claims description 22
- 150000002596 lactones Chemical class 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 11
- 241000187747 Streptomyces Species 0.000 claims description 8
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical class C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 28
- 235000002639 sodium chloride Nutrition 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- -1 amino acid salts Chemical class 0.000 description 14
- 239000002994 raw material Substances 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000003125 aqueous solvent Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 241000187180 Streptomyces sp. Species 0.000 description 5
- 230000033444 hydroxylation Effects 0.000 description 5
- 238000005805 hydroxylation reaction Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 4
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229910052500 inorganic mineral Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011707 mineral Chemical class 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000186361 Actinobacteria <class> Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 2
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000007273 lactonization reaction Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical compound CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GMKMEZVLHJARHF-WHFBIAKZSA-N LL-2,6-diaminopimelic acid Chemical compound OC(=O)[C@@H](N)CCC[C@H](N)C(O)=O GMKMEZVLHJARHF-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 235000002233 Penicillium roqueforti Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 150000001218 Thorium Chemical class 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 150000002815 nickel Chemical class 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- LXZBFUBRYYVRQJ-AXHZAXLDSA-M sodium;(3r,5r)-7-[(1s,2s,6r,8s,8ar)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate Chemical class [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C=C21 LXZBFUBRYYVRQJ-AXHZAXLDSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は式
を有するカルボン酸、その薬理上許容しうる塩、
そのエステルまたはその閉環ラクトン体からなる
3″−ヒドロキシ−ML−236B誘導体およびその製
造法に関する。
従来、前記一般式()において、3″位のヒド
ロキシ基が水素原子で置換されたML−236B誘導
体は例えば特開昭50−155690号、同53−56314号、
同53−84954号に記載されており、また、6′位の
水素原子がメチル基で置換されたMB−530B誘
導体は米国特許第4376863号に記載されており、
いずれもコレステロール合成阻害作用を示すこと
が知られている。
本発明者らは、前記一般式()を有するカル
ボン酸、その薬理上許容しうる塩、そのエステル
またはその閉環ラクトン体がいずれもコレステロ
ール合成阻害作用を示すことを見出し、本発明を
完成した。
本発明の前記一般式()を有する化合物の薬
理上許容しうる塩としては例えば金属塩、アミノ
酸塩またはアミン塩である。金属塩としては例え
ばナトリウム、カリウムなどのアルカリ金属塩、
カルシウム、マグネシウムなどのアルカリ土類金
属塩、およびアルミニウム塩、鉄塩、亜鉛塩、銅
塩、ニツケル塩およびコバルト塩などがあげられ
るが、この中、アルカリ金属塩、アルカリ土類金
属塩およびアルミニウム塩が好適であり、さらに
ナトリウム塩、カリウム塩、カルシウム塩および
アルミニウム塩が最も好適である。アミノ酸塩と
しては例えばアルギニン、リジン、ヒスチジン、
α,γ−ジアミノ酪酸、オルニチンなどの塩基性
アミノ酸が好適である。アミノ塩としては例えば
t−オクチルアミン、ジベンジルアミン、ジシク
ロヘキシルアミン、モルホリン、D−フエニルグ
リシンアルキルエステル、D−グルコサミンなど
が好適である。
前記一般式()を有する化合物のエステルと
しては、例えばメチル、エチル、プロピル、イソ
プロピル、ブチル、イソブチル、ペンチルなどの
アルキルエステルをあげることができる。好適に
はメチルである。
前記一般式()を有する化合物の閉環ラクト
ン体とは、式()が次の閉環構造式で示される
化合物をいう。
本発明によつて得られる前記一般式()を有
するカルボン酸、その薬理上許容しうる塩、その
エステルまたはその閉環ラクトン体としては、例
えば以下に記載する化合物をあげることができ
る。
1 3″−ヒドロキシ−ML−236Bカルボン酸
2 3″−ヒドロキシ−ML−236Bカルボン酸ナト
リウム塩
3 3″−ヒドロキシ−ML−236Bカルボン酸カリ
ウム塩
4 3″−ヒドロキシ−ML−236Bカルボン酸カル
シウム塩
5 3″−ヒドロキシ−ML−236Bカルボン酸アル
ミニウム塩
6 3″−ヒドロキシ−ML−236Bカルボン酸アル
ギニン塩
7 3″−ヒドロキシ−ML−236Bカルボン酸リジ
ン塩
8 3″−ヒドロキシ−ML−236Bカルボン酸t−
オクチルアミン塩
9 3″−ヒドロキシ−ML−236Bカルボン酸D−
フエニルグリシンエチルエステル塩
10 3″−ヒドロキシ−ML−236Bカルボン酸メチ
ルエステル
11 3″−ヒドロキシ−ML−236ラクトン体
本発明の前記一般式()においては、置換分
の配置により種々の幾何異性体が存在する。
また、不斉炭素原子の存在により種々の光学異
性体も存在する。前記一般式()においては、
これらの異性体およびこれらの異性体の混合物が
すべて単一の式で示されている。従つて、本発明
においては、前記一般式()を有するカルボン
酸、その薬理上許容しうる塩、そのエステルまた
はその閉環ラクトン体には、これらの異性体のみ
ならず、これらの異性体の混合物をも全て包むも
のである。
本発明の目的化合物は、コレステロールの合成
を阻害することにより血中の脂質を低下させる作
用を有し、例えば高脂血症治療剤、動脈硬化予防
薬として医薬に使用することができる。
これらの化合物は経口的または非経口的に例え
ばカプセル剤、錠剤、注射剤等の形で投与するこ
とができる。投与量は年令、症状、体重等によつ
て異なるが、通常は成人に対し1日約0.2〜200mg
を3〜4回に分けて投与される。しかし必要に応
じてそれ以上の量を使用することもできる。
本発明の原料物質である例えばML−236Bラク
トン体およびML−236Bカルボン酸は前述の如く
既知物質であり、青カビの一種ペニシリウム・チ
トリヌムの代謝産物より分離、精製される。その
化学構造式は次式
および
で示される通りであり、実験動物から分離した酵
素系や培養細胞系においてコレステロールの生合
成をその律速酵素の3−ヒドロキシ−3−メチル
グルタリル・コエンザイムAリダクターゼと競合
することにより阻害し、動物の個体レベルにおい
ても強力な血清コレステロールの低下作用を示す
ことが知られている(特開昭50−155690号、アテ
ロスクレローシス(Atherosclerosis),32,307
〜313,1979年)。
本発明の目的化合物は式
を有するカルボン酸、その薬理上許容しうる塩、
そのエステルまたはその閉環ラクトン体からなる
ML−236B誘導体を、3″−ヒドロキシ化変換菌ま
たはその無細胞抽出液と接触させて酵素的に水酸
化し、次いで得られた変換反応物を所望により加
水分解反応、塩形成反応、エステル化反応または
ラクトン化反応に付し、反応液から採取すること
によつて得られる。
前記原料化合物を前記一般式()を有するカ
ルボン酸、その薬理上許容しうる塩、そのエステ
ルまたはその閉環ラクトン体に変換せしめ得る微
生物としてはストレプトミセス属があげられる。
ストレプトミセス属に属する微生物の中、特に
ストレプトミセス・エスピー
(Streptomycessp.)SANK62285(微工研条寄
第1142号)
ストレプトミセス・エスピー
(Streptomycessp.)SANK62385(微工研条寄
第1143号)
ストレプトミセス・エスピー
(Streptomycessp.)SANK62485(微工研条寄
第1144号)
が90%以上の変換率でML−236B誘導体を3″−ヒ
ドロキシ−ML−236B誘導体に変換する能力を有
する。
これらの菌株の菌学的性状は次の通りである。
1 形態学的特徴
形態はISP〔インターナシヨナル・ストレプト
マイセス・プロジエクト(International
Streptomyces Project)〕規定の培地上、28℃、
14日間培養後、光学および電子顕微鏡下で観察し
た。SANK62285、SANK62385および
SANK62485株とも基生菌糸は分枝して良く伸長
し、気菌糸は単純分枝である。
SANK62285株の胞子鎖の形態は直状を示し、
胞子は球形〜卵形でその表面構造は平滑を示す。
SANK62385株およびSANK62485株の胞子鎖の
形態は螺旋状を示し、胞子は球形〜楕円形で、そ
の表面構造は平滑である。SANK62285、
SANK62385およびSANK62485株にはいずれも
気菌糸の車軸分枝、菌核、胞子のうなどの特殊器
官は観察されなかつた。
2 各種培養基上の諸性質
各種培養基上で28℃、14日間培養後の性状は第
1〜3表に示す通りである。色調の表示は日本色
彩研究所版、“標準色票”のカラーチツプ・ナン
バーを表わす。
The present invention is based on the formula a pharmacologically acceptable salt thereof,
Consists of its ester or its ring-closed lactone
This invention relates to a 3"-hydroxy-ML-236B derivative and a method for producing the same. Conventionally, ML-236B derivatives in which the hydroxy group at the 3" position in the above general formula () is substituted with a hydrogen atom have been disclosed, for example, in JP-A-50-155690. , No. 53-56314,
53-84954, and the MB-530B derivative in which the hydrogen atom at the 6' position is substituted with a methyl group is described in U.S. Patent No. 4,376,863.
All are known to exhibit cholesterol synthesis inhibitory effects. The present inventors have completed the present invention by discovering that a carboxylic acid having the general formula (), its pharmacologically acceptable salt, its ester, or its ring-closed lactone form all exhibit a cholesterol synthesis inhibitory effect. Pharmaceutically acceptable salts of the compound having the general formula () of the present invention include, for example, metal salts, amino acid salts, and amine salts. Examples of metal salts include alkali metal salts such as sodium and potassium;
Examples include alkaline earth metal salts such as calcium and magnesium, and aluminum salts, iron salts, zinc salts, copper salts, nickel salts, and cobalt salts, among which alkali metal salts, alkaline earth metal salts, and aluminum salts are preferred, and the sodium, potassium, calcium and aluminum salts are most preferred. Examples of amino acid salts include arginine, lysine, histidine,
Basic amino acids such as α,γ-diaminobutyric acid and ornithine are preferred. Suitable amino salts include t-octylamine, dibenzylamine, dicyclohexylamine, morpholine, D-phenylglycine alkyl ester, and D-glucosamine. Examples of the ester of the compound having the general formula () include alkyl esters such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and pentyl. Methyl is preferred. The ring-closed lactone of the compound having the general formula () above refers to a compound in which the formula () is represented by the following ring-closed structural formula. Examples of the carboxylic acid having the general formula (), its pharmacologically acceptable salt, its ester, or its ring-closed lactone derivative obtained by the present invention include the compounds described below. 1 3″-hydroxy-ML-236B carboxylic acid 2 3″-hydroxy-ML-236B carboxylic acid sodium salt 3 3″-hydroxy-ML-236B carboxylic acid potassium salt 4 3″-hydroxy-ML-236B carboxylic acid calcium salt 5 3″-hydroxy-ML-236B carboxylic acid aluminum salt 6 3″-hydroxy-ML-236B carboxylic acid arginine salt 7 3″-hydroxy-ML-236B carboxylic acid lysine salt 8 3″-hydroxy-ML-236B carboxylic acid t-
Octylamine salt 9 3″-hydroxy-ML-236B carboxylic acid D-
Phenylglycine ethyl ester salt 10 3″-Hydroxy-ML-236B carboxylic acid methyl ester 11 3″-Hydroxy-ML-236 lactone The general formula () of the present invention has various geometric isomerisms depending on the arrangement of the substituents. A body exists. Furthermore, various optical isomers also exist due to the presence of asymmetric carbon atoms. In the general formula (),
All of these isomers and mixtures of these isomers are shown in a single formula. Therefore, in the present invention, the carboxylic acid having the general formula (), its pharmacologically acceptable salt, its ester, or its ring-closed lactone includes not only these isomers but also mixtures of these isomers. It also encompasses everything. The object compound of the present invention has an effect of lowering blood lipids by inhibiting cholesterol synthesis, and can be used in medicine, for example, as a therapeutic agent for hyperlipidemia or an agent for preventing arteriosclerosis. These compounds can be administered orally or parenterally, for example, in the form of capsules, tablets, injections, and the like. The dosage varies depending on age, symptoms, body weight, etc., but it is usually about 0.2 to 200 mg per day for adults.
is administered in 3 to 4 divided doses. However, larger amounts can be used if desired. The raw materials of the present invention, such as ML-236B lactone and ML-236B carboxylic acid, are known substances as described above, and are separated and purified from metabolites of Penicillium titrinum, a type of blue mold. Its chemical structure is as follows and As shown by It is known that it exhibits a strong serum cholesterol-lowering effect even at the individual level (Japanese Patent Application Laid-open No. 155690/1983, Atherosclerosis, 32 , 307).
~313, 1979). The object compound of the present invention has the formula a pharmacologically acceptable salt thereof,
Consists of its ester or its ring-closed lactone
The ML-236B derivative is enzymatically hydroxylated by contacting it with a 3″-hydroxylated conversion bacterium or its cell-free extract, and then the resulting conversion reaction product is subjected to hydrolysis reaction, salt formation reaction, and esterification as desired. It is obtained by subjecting the raw material compound to a carboxylic acid having the general formula (), a pharmacologically acceptable salt thereof, an ester thereof, or a closed ring lactone thereof. Among the microorganisms belonging to the genus Streptomyces, Streptomyces sp. ) SANK62385 (Feikoken Article No. 1143) Streptomyces sp. SANK62485 (Feikoken Article No. 1144) converts ML-236B derivatives into 3″-hydroxy-ML with a conversion rate of over 90%. It has the ability to convert into -236B derivatives. The mycological properties of these strains are as follows. 1 Morphological characteristics The morphology is ISP (International Streptomyces progeny).
Streptomyces Project)] on specified medium, 28℃,
After culturing for 14 days, it was observed under light and electron microscopes. SANK62285, SANK62385 and
In both SANK62485 strains, the basal hyphae are branched and elongate well, and the aerial hyphae are simply branched. The shape of the spore chain of SANK62285 strain is straight;
The spores are spherical to oval in shape and have a smooth surface structure.
The spore chains of the SANK62385 and SANK62485 strains have a spiral shape, the spores are spherical to oval, and the surface structure is smooth. SANK62285,
Special organs such as axle branches of aerial hyphae, sclerotia, and sporangia were not observed in either SANK62385 or SANK62485 strains. 2. Properties on various culture media The properties after culturing on various culture media at 28°C for 14 days are as shown in Tables 1 to 3. The color tone display represents the color chip number of the "Standard Color Chart" published by the Japan Color Research Institute.
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】【table】
【表】
3 生理学的性質
SANK62285、SANK62385およびSANK62485
株の生理学的性質は第4〜6表に示す通りであ
る。[Table] 3 Physiological properties SANK62285, SANK62385 and SANK62485
The physiological properties of the strains are shown in Tables 4-6.
【表】【table】
【表】【table】
【表】
ゼラチンの液化 陽性
[Table] Liquefaction of gelatin positive
【表】
また、プリドハム・ゴトリーブ寒天培地を使用
して、14日間培養後炭素源の資化性を調べた。
SANK62285、SANK62385およびSANK62485株
は炭素源無添加の対照培地でも若干の生育がみら
れるため、正確な資化性を記述することは困難で
ある。尚、参考のため第7表に対照を−とした時
の相対的な資化性を示した。[Table] In addition, using Pridham-Gotlieb agar medium, the assimilation of carbon sources was investigated after 14 days of culture.
SANK62285, SANK62385, and SANK62485 strains show some growth even in a control medium without carbon source addition, so it is difficult to describe their accurate assimilation ability. For reference, Table 7 shows the relative assimilation ability when the control is -.
【表】
4 菌体成分について
SANK62285、SANK62385およびSANK62485
株の細胞壁はビー・ベツカーらの方法〔B.
Beckeret al.,アプライド・マイクロバイオロジ
ー(Applied Microbiology),12巻,421〜423
頁,1964年〕に従い検討した結果、L,L−ジア
ミノピメリン酸およびグリシンが検出されたこと
から、細胞壁タイプであることが確認された。
また、SANK62285、SANK62385および
SANK62485株の全細胞中の糖成分をエム・ピ
ー・レシエバリエの方法〔M.P.Lechevalier,ジ
ヤーナル・オブ・ラボラトリイ・アンド・クリニ
カル・メデイシン(Journal of Laboratory and
Clinical Madicine),71巻,934頁,1968年〕に
従い検討した結果、特徴的なパターンは認められ
なかつた。
以上のことから、本菌株3株は放線菌の中でも
ストレプトマイセス属に属することが判明したの
で、ストレプトマイセス・エスピー
(Streptomyces sp.)SANK62285、SANK62385
およびSANK62485と命名された。
なお、SANK62285、SANK62385および
SANK62485株の同定はISP〔ジ・インターナシヨ
ナル・ストレプトマイセス・プロジエクト(The
International Streptomyces Project)〕基準、
バージーズ・マニユアル(Bergey's Manual of
Determinative Bacteriology)第8版、ジ・ア
クチノミセイテス(The Actinomycetes)第2
巻および放線菌に関する最近の文献によつて行つ
た。
以上、SANK62285、SANK62385および
SANK62485株について説明したが、枚線菌の諸
性質は一定したものではなく、自然的、人工的に
容易に変化することは周知のとおりであり、本発
明で使用しうる菌株はストレプトマイセス属に属
し、ML−236B誘導体を3″−ヒドロキシ−ML−
236B誘導体に変換し得る菌株すべてを包含する
ものである。
本発明の方法を実施するに際して、酵素的に水
酸化する方法としては、変換菌をその生育に適し
た培養条件下で培養し、a○原料化合物を培地中に
添加して接触させる方法b○変換菌を培養・集菌
し、得られた変換菌菌体を原料化合物と接触させ
る方法、およびc○変換菌菌体から調製した無細胞
抽出液を原料化合物と接触させる方法などが採用
される。
変換菌の培養方法としては、通常微生物が利用
しうる栄養物を含有する培地で培養することがで
きる。栄養源としては一般微生物培養に利用され
る公知のものが使用できる。例えば炭素源として
グルコース、シユークロース、澱粉、グリセリ
ン、水飴、糖密、大豆油等を使用しうる。また窒
素源としては大豆粉、水麦胚芽、肉エキス、ペプ
トン、コーンスチープリカー、乾燥酵母、硫酸ア
ンモニウム等を使用しうる。その他必要に応じて
食塩、塩化カリ、炭酸カルシウム、隣酸塩等の無
機塩のほか、菌の発育を助け、前記水酸化能を有
する酵素の生産促進に必要な添加物を適宜組合せ
使用することができる。培養方法としては微生物
一般に用いられる培養法例えば液体培養法が可能
であり、工業的には深部培養法が適している。
培養は好気的条件下で行なわれ、培養温度は20
〜37℃、好適には26〜28℃である。
a○法は、原料化合物を添加し培養することによ
つて行なわれる。添加時期は、使用する変換菌の
至適培養条件、特に培養装置、培地組成、培地温
度等により異なるが、変換菌の水酸化能が高まり
はじめる時期がよく、通常は変換菌の培養開始後
2〜3日経過した時点が好ましい。原料化合物の
添加量は培地に対し0.01〜5.0%の範囲から選ば
れるが、0.05〜0.5%の範囲が好適である。原料
化合物添加後の培養は好気的条件で上記培養温度
で行なわれる。培養期間は原料化合物の添加後3
〜5日である。
b○法は、上記の方法により変換菌を少量の基質
の存在下で培養し、変換菌の水酸化能が最大とな
るまで培養する。即ち、水酸化能は培地の種類、
温度等によつて異なるが、通常は培養開始後4〜
5日で最大となるので、この時点で培養を終了す
る。集菌は培養物を遠心分離、過等の方法に付
すことによつて行なわれる。集菌された変換菌菌
体は通常生理食塩水、緩衝液等で洗浄して使用す
るのが好ましい。
このようにして得られた変換菌菌体を原料化合
物と接触させるには、通常は水性媒体中、例えば
PH5〜9の隣酸塩緩衝液中で行なわれる。反応温
度は20〜45℃、好適には25〜30℃である。原料化
合物の濃度は通常0.01〜5.0%の範囲から選ばれ
る。反応時間は原料化合物の濃度、反応温度等に
よるが、通常1〜5日位である。
c○方法での無細胞抽出液は、上記の方法で得ら
れた変換菌菌体に物理的または化学的手段を適用
し、例えば磨砕、超音波処理等によつて菌体破壊
物として、また界面活性剤、酵素処理等によつて
菌体溶解液として得られる。
このようにして得られた無細胞抽出液を原料化
合物と接触させる方法は、上記の変換菌菌体を原
料化合物と接触させる方法と同様に行なわれる。
変換反応終了後、目的化合物は生成物から既知
の方法で直接採取、分離、精製することができ
る。例えば生成物を過し、得られた液を酢酸
エチルのような水と混和しにくい有機溶媒で抽出
し、抽出液から溶媒を留去させたのち、得られた
粗目的化合物をシリカゲル、アルミナ等を用いた
カラムクロマトグラフに付し、適切な溶離剤で溶
出することによつて分離、精製することができ
る。
さらに、得られた生成物は所望により、化学的
常法に従つて加水分解反応、塩形成反応、エステ
ル化反応またはラクトン化反応に付すことによつ
て日的化合物に変え、容易に採取することができ
る。
これらの方法はいずれも常法であり、例えば次
のような方法である。
式()を有するカルボン酸は、変換反応の生
成物がカルボン酸塩である場合、得られた液を
PH4以下、好ましくはPH3〜4に調整することに
よつて得られる。使用される酸としては目的化合
物に影響を与えるものでなければ有機酸または鉱
酸等に限定はなく、例えばトリフルオロ酢酸、塩
酸、硫酸などが好適に使用される。
このようにして得られたカルボン酸は、抽出、
洗浄、脱水等の処理をした後、以下の反応に使用
することができる。
式()を有するカルボン酸の金属塩は、該金
属の水酸化物、炭酸塩等を水性溶媒中で上記カル
ボン酸と接触させることによつて得られる。使用
される水性溶媒としては例えば水;メタノール、
エタノールのようなアルコール類、アセトン、n
−ヘキサン、酢酸エチルなどの有機溶媒と水との
混合溶媒が好適である。特に親水性有機溶媒と水
との混合溶媒が好適である。反応は通常室温付近
で好適に行なわれるが、必要に応じて加熱下で行
つてもよい。
式()を有するカルボン酸のアミン塩は、ア
ミンを水性溶媒中で上記カルボン酸と接触させる
ことによつて得られる。使用される水性溶媒とし
ては例えば水;メタノール、エタノールなどのア
ルコール類、テトラヒドロフランなどのエーテル
類、アセトニトリルなどのニトリル類と水との混
合溶媒等をあげることができるが、好ましくは含
水アセトンである。反応は通常PH7〜8.5で室温
以下、特に5〜10℃で好適に行なわれる。反応は
瞬時に完了する。あるいは例えば上記で得られた
カルボン酸金属塩を水性溶媒に溶解し、次いで目
的のアミンの鉱酸塩(例えば塩酸塩など)を上記
条件下で添加し、塩交換反応により得ることもで
きる。
式()を有するカルボン酸のアミノ塩は、ア
ミノ酸を水性溶媒中で上記カルボン酸と接触させ
ることによつて得られる。使用される水性溶媒と
しては例えば水;メタノール、エタノールなどの
アルコール類、テトラヒドロフランなどのエーテ
ル類と水との混合溶媒等をあげることができる。
反応は通常加熱下、好ましくは50〜60℃付近で行
なわれる。
式()を有するカルボン酸のアルキルエステ
ルは、上記で得られたカルボン酸をアルコールと
接触させることによつて得られる。この際、触媒
としては塩酸、硫酸などの鉱酸あるいはフツ化ホ
ウ素、酸性イオン変換樹脂などが用いられ、溶媒
としては同一のアルコールまたはベンゼン、クロ
ロホルム、エーテル等反応に関与しないものが使
用される。あるいは、上記で得られたカルボン酸
をジアゾアルカンと接触させることによつて得ら
れる。反応は通常ジアゾアルカンのエーテル溶液
と接触させることによつて行なわれる。あるい
は、上記で得られたカルボン酸の金属塩にハロゲ
ン化アルキルを接触させることによつて得られ
る。使用される溶媒としては例えばジメチルホル
ムアミド、テトラヒドロフラン、ジメチルスルホ
キシド、アセトンなどが好適である。
反応はいずれも室温付近で好適に行なわれる
が、反応系の種類によつては必要に応じて加熱下
で行なつてもよい。
式()を有するカルボン酸のラクトン体は、
上記で得られたカルボン酸を触媒量の酸と接触さ
せることによつて得られる。使用される酸として
は、例えばトリフルオロ酢酸、塩酸、硫酸などの
有機酸または鉱酸が好適である。反応は通常室温
付近で好適に行なわれる。
さらに、このようにして得られた目的化合物を
原料として、上記の化学的常法に従つて、他の目
的化合物に変えることもできる。
このようにして得られた目的化合物は種々の方
法を適宜組合わせることによつて採取、分離、精
製することができる。例えば活性炭、シリカゲル
等の各種担体を用いる吸着またはイオン交換クロ
マト、あるいはセフアデツクスカラムによるゲル
過、エーテル、酢酸エチル、クロロホルムなど
の有機溶媒を用いての抽出などにより行なわれ
る。
特に異性体の分離は、変換反応終了後、または
所望工程の終了後の適切な時期に上記の分離精製
手段により行うことができる。
次に実施例を示すが、本発明はこれらに限定さ
れるものではない。
実施例 1
3″−ヒドロキシ−ML−236ラクトン体
グルコース20、ペプトン10、酵母エキス1.0
(g/)PH7.0からなる培地100mlを含有する500
ml容の三角フラスコ4本にストレプトミセス・エ
スピーSANK62285株を接種し、28℃で48時間振
盪培養(220r.p.m)した。得られた種培養液150
mlを上記と同じ組成の培地15を含む30容ジヤ
ーフアーメンター2基にそれぞれ移し、消泡剤と
してCB−442を0.01%加えて通気量15/分、内
圧1.0Kg/cm2、撹拌速度100〜200r.p.m培養温度28
℃の条件下で45時間培養した。これにML−236
カルボン酸ナトリウム塩を最終濃度で0.1%にな
るように添加して更に50時間培養を続けた。培養
終了後、培養液を過し、液を得た。
15ジヤー2基分の液26をHP−20樹脂2
にSV4〜5で吸着させたのち水洗(8)し、
30%アセトン−水3、50%アセトン−水8の
溶媒で溶出した。50%アセトン−水溶出分画8
を減圧濃縮しアセトンを除去した。濃縮液4.6
を6N−塩酸でPH2.8〜3.0としたのち等量の酢酸エ
チル(4×2)で抽出した。この酢酸エチル抽
出液を飽和食塩水(4×2)で水洗後、無水硫
酸ナトリウムで乾燥して濃縮し油状の濃縮物20g
を得た。得られた油状濃縮物20gを乾燥した酢酸
エチル100mlに溶解し、これにトリフルオロ酢酸
0.5mlを加え50℃、3時間放置しラクトン化を行
つた。反応液を酢酸エチル400mlで希釈し、1%
重炭酸ナトリウム液で処理したのち飽和食塩水で
水洗、無水硫酸ナトリウムで乾燥した。この酢酸
エチル液を濃縮(100ml)し、析出した3″−ヒド
ロキシ−ML−236Bラクトン体の粗結晶12.8gを
別した。この粗結晶の一部をシリカゲルカラム
クロマト精製(Si−60,n−ヘキサン−アセトン
0〜50v/v%)して得られる純品3″−ヒドロキ
シ−ML−236Bラクトン体は以下の物理定数を示
す。
1 分子式:C23H34O6
2 分子量:406(SIMS質量分析スペクトラム:
QM+H,407)
3 赤外線吸収スペクトル:νnaxcm-1
KBr中で測定した赤外線吸収スペクトルは第
1図に示す通りである。
4 炭素−13−核磁気共鳴スペクトル:δ:ppm
重クロロホルム中、内部基準にテトラメチルシ
ランを使用して測定した炭素−13−核磁気共鳴ス
ペクトル(22.5MHz)は、以下のケミカケルシフ
ト(ppm)および多重度を示す。
ケミカケルシフト 多重度
1 10.9 Q
2 13.8 Q
3 20.0 Q
4 20.9 T
5 23.6 T
6 26.2 T
7 30.9 D
8 32.7 T
9 36.9 D
10 36.0 T
11 37.6 D
12 38.6 T
13 45.9 D
14 62.5 D
15 68.1 D
16 68.4 D
17 76.2 D
18 123.6 D
19 128.1 D
20 132.8 D
21 133.7 S
22 170.8 S
23 175.7 S
実施例 2
3″−ヒドロキシ−ML−236Bカルボン酸ナトリ
ウム塩
実施例1で得られた3″−ヒドロキシ−ML−
236Bラクトン体2.0gをメタノール200mlに溶解
し、これに蒸留水50mlを加えた。この溶液にほぼ
等モル量の水酸化ナトリウム液(0.25g/40ml
H2O)を40〜50℃で滴加した。この間ナトリウ
ム塩の生成は液体クロマト法で確認した。滴加後
約2時間で反応液をN−塩酸でPH8.5に調整した
のち減圧濃縮(50ml)しメタノールを除去し、水
層を凍結乾燥することにより3″−ヒドロキシ−
ML−236Bカルボン酸ナトリウム塩2.6gを得た。
3″−ヒドロキシ−ML−236Bカルボン酸ナトリウ
ム塩は以下の物理定数を示す。
1 分子式:C23H35O7Na
2 赤外線吸収スペクトル:νnaxcm-1
KBr中で測定した赤外線吸収スペクトルは第
2図に示す通りである。
3 プロトン−核磁気共鳴スペクトル:δ:ppm
重水中、内部基準にテトラメチルシランを使用
して測定したプロトン−核磁気共鳴スペクトル
(270PH)は第3図に示す通りである。
4 炭素−13−核磁気共鳴スペクトル:δ:ppm
重水中、内部基準にテトラメチルシランを使用
して測定した炭素−13−核磁気共鳴スペクトル
(22.5MHz)は、以下のケミカケルシフト(ppm)
および多重度を示す。
ケミカケルシフト 多重度
1 13.8 Q
2 14.7 Q
3 21.7 Q
4 21.9 D
5 25.2 T
6 27.0 D
7 31.8 D
8 35.5 T
9 38.2 T
10 38.3 T
11 44.6 T
12 45.6 T
13 48.6 D
14 68.8 D
15 69.4 D
16 70.0 D
17 71.1 D
18 124.0 D
19 129.0 D
20 134.5 D
21 135.0 S
22 177.7 S
23 180.9 S
実施例 3
ストレプトミセス・エスピーSANK62285株の
代りにそれぞれストレプトミセス・エスピー
SANK62385株および同SANK62485株を用いて、
実施例1および2と同様に実施して、3″−ヒドロ
キシ−ML−236Bラクトン体および3″−ヒドロキ
シ−ML−236Bカルボン酸ナトリウム塩が得られ
た。
物理定数は実施例1および2で得られたものと
同じであつた。
試験例 コレステロール合成阻害作用
前記一般式()を有するカルボン酸、その薬
理上許容しうる塩、そのエステルまたはその閉環
ラクトン体からなる3″−ヒドロキシ−ML−236B
誘導体はコレステロール合成経路上の律速酵素と
して知られる3−ヒドロキシ−3−メチルグルタ
リル・コエンザイムAリダクーゼ(3−hydroxy
−3−methyl−glutaryl−Co A reductase)
を特異的に阻害することが分つた。これら化合物
のコレステロール合成阻害作用〔ジヤーナル・オ
ブ・バイオロジカル・ケミストリー(J.Biol.
Chem.)234巻2835頁(1959年)記載の方法で測
定〕を第8表に示す。[Table] 4 Regarding bacterial components SANK62285, SANK62385 and SANK62485
The cell wall of the strain was determined using the method of B. Betzker et al. [B.
Beckeret al., Applied Microbiology, vol. 12, 421-423.
Page, 1964], L,L-diaminopimelic acid and glycine were detected, so it was confirmed that it was a cell wall type.
Also SANK62285, SANK62385 and
Sugar components in whole cells of SANK62485 strain were determined using the MP Lechevalier method [MPLechevalier, Journal of Laboratory and Clinical Medicine].
Clinical Medicine, Vol. 71, p. 934, 1968], no characteristic pattern was observed. From the above, it was found that these three strains belong to the genus Streptomyces among actinomycetes, and therefore Streptomyces sp. SANK62285, SANK62385
and was named SANK62485. In addition, SANK62285, SANK62385 and
Identification of SANK62485 strain was carried out by ISP [The International Streptomyces Project].
International Streptomyces Project) Standards,
Bergey's Manual of
Determinative Bacteriology 8th edition, The Actinomycetes 2nd edition
volume and recent literature on actinomycetes. Above, SANK62285, SANK62385 and
Although the SANK62485 strain has been explained, it is well known that the properties of Streptomyces spp. are not constant and can easily change naturally or artificially. ML-236B derivative belongs to 3″-hydroxy-ML-
This includes all strains that can be converted into 236B derivatives. When carrying out the method of the present invention, methods for enzymatic hydroxylation include a method in which the converting bacteria are cultured under culture conditions suitable for their growth, and a○ a raw material compound is added to the medium and brought into contact b○ A method of cultivating and collecting the converting bacteria and contacting the obtained converted bacteria cells with a raw material compound, and a method of contacting a cell-free extract prepared from c○ converting bacteria cells with the raw material compound, etc. are adopted. . The converting bacteria can be cultured in a medium containing nutrients that can be used by microorganisms. As the nutrient source, any known nutrient source used for general microbial culture can be used. For example, glucose, sucrose, starch, glycerin, starch syrup, molasses, soybean oil, etc. can be used as the carbon source. Further, as the nitrogen source, soybean flour, barley germ, meat extract, peptone, corn steep liquor, dried yeast, ammonium sulfate, etc. can be used. In addition to other inorganic salts such as salt, potassium chloride, calcium carbonate, and phosphate salts, additives necessary to support the growth of bacteria and promote the production of the enzymes having the above-mentioned hydroxylation ability may be used in combination as appropriate. I can do it. As a culture method, a culture method generally used for microorganisms, such as a liquid culture method, can be used, and a deep culture method is suitable for industrial use. Cultivation was carried out under aerobic conditions, with a culture temperature of 20
~37°C, preferably 26-28°C. The a○ method is carried out by adding and culturing a raw material compound. The timing of addition varies depending on the optimal culture conditions of the converting bacteria used, especially the culture equipment, medium composition, medium temperature, etc., but it is best to add it when the hydroxylation ability of the converting bacteria begins to increase, usually 2 days after the start of culturing of the converting bacteria. Preferably, after ~3 days have elapsed. The amount of the raw material compound to be added to the medium is selected from the range of 0.01 to 5.0%, preferably from 0.05 to 0.5%. Cultivation after addition of the raw material compound is carried out under aerobic conditions at the above-mentioned culture temperature. The culture period is 3 after the addition of the raw material compound.
~5 days. In the b○ method, converted bacteria are cultured in the presence of a small amount of substrate by the method described above, and cultured until the hydroxylation ability of the converted bacteria reaches its maximum. In other words, the hydroxylation ability depends on the type of medium,
Although it varies depending on the temperature etc., it usually takes 4 to 4 hours after the start of culture.
Since it reaches its maximum level in 5 days, the culture is terminated at this point. Bacterial collection is performed by subjecting the culture to centrifugation, straining, etc. It is preferable that the collected converted bacterial cells be washed with normal saline, buffer solution, etc. before use. In order to bring the thus obtained converted bacterial cells into contact with the starting compound, it is usually carried out in an aqueous medium, e.g.
It is carried out in a phosphate buffer with a pH of 5-9. The reaction temperature is 20-45°C, preferably 25-30°C. The concentration of the raw material compound is usually selected from the range of 0.01 to 5.0%. The reaction time depends on the concentration of the raw material compound, the reaction temperature, etc., but is usually about 1 to 5 days. The cell-free extract obtained by the c○ method is obtained by applying physical or chemical means to the converted bacterial cells obtained by the above method, for example, by grinding, ultrasonication, etc., to obtain a cell-free extract. It can also be obtained as a bacterial cell lysate by treatment with a surfactant or an enzyme. The method of contacting the cell-free extract thus obtained with the raw material compound is carried out in the same manner as the method of contacting the converted bacterial cells with the raw material compound described above. After the conversion reaction is completed, the target compound can be directly collected, separated, and purified from the product by known methods. For example, the product is filtered, the resulting liquid is extracted with an organic solvent that is not easily miscible with water such as ethyl acetate, the solvent is distilled off from the extracted liquid, and the resulting crude target compound is extracted with silica gel, alumina, etc. It can be separated and purified by subjecting it to column chromatography and eluting with an appropriate eluent. Furthermore, the obtained product can be converted into a common compound by subjecting it to a hydrolysis reaction, salt formation reaction, esterification reaction, or lactonization reaction according to conventional chemical methods, and can be easily collected. I can do it. All of these methods are conventional methods, such as the following method. Carboxylic acids with formula () are used when the product of the conversion reaction is a carboxylate salt, and the resulting liquid
It can be obtained by adjusting the pH to 4 or less, preferably 3 to 4. The acid used is not limited to organic acids or mineral acids as long as it does not affect the target compound; for example, trifluoroacetic acid, hydrochloric acid, sulfuric acid, etc. are preferably used. The carboxylic acid thus obtained is extracted,
After processing such as washing and dehydration, it can be used in the following reaction. A metal salt of a carboxylic acid having the formula () can be obtained by contacting a hydroxide, carbonate, etc. of the metal with the above carboxylic acid in an aqueous solvent. Examples of aqueous solvents used include water; methanol;
Alcohols such as ethanol, acetone, n
- A mixed solvent of water and an organic solvent such as hexane or ethyl acetate is suitable. Particularly suitable is a mixed solvent of a hydrophilic organic solvent and water. The reaction is usually suitably carried out at around room temperature, but may be carried out under heating if necessary. Amine salts of carboxylic acids having formula () are obtained by contacting amines with the above carboxylic acids in an aqueous solvent. Examples of the aqueous solvent used include water; alcohols such as methanol and ethanol; ethers such as tetrahydrofuran; and mixed solvents of water and nitriles such as acetonitrile; preferred is aqueous acetone. The reaction is usually suitably carried out at a pH of 7 to 8.5 and below room temperature, particularly at 5 to 10°C. The reaction is completed instantly. Alternatively, the carboxylic acid metal salt obtained above can be dissolved in an aqueous solvent, and then a mineral acid salt (eg, hydrochloride) of the desired amine can be added under the above conditions to obtain the salt exchange reaction. The amino salt of a carboxylic acid having the formula () can be obtained by contacting an amino acid with the above carboxylic acid in an aqueous solvent. Examples of the aqueous solvent used include water; a mixed solvent of water and alcohols such as methanol and ethanol; and ethers such as tetrahydrofuran.
The reaction is usually carried out under heating, preferably around 50 to 60°C. The alkyl ester of a carboxylic acid having the formula () can be obtained by contacting the carboxylic acid obtained above with an alcohol. In this case, as a catalyst, a mineral acid such as hydrochloric acid or sulfuric acid, or boron fluoride, or an acidic ion conversion resin is used, and as a solvent, a solvent that does not participate in the reaction, such as the same alcohol or benzene, chloroform, or ether, is used. Alternatively, it can be obtained by contacting the carboxylic acid obtained above with a diazoalkane. The reaction is usually carried out by contacting with an ethereal solution of the diazoalkane. Alternatively, it can be obtained by contacting the metal salt of carboxylic acid obtained above with an alkyl halide. Suitable solvents to be used include, for example, dimethylformamide, tetrahydrofuran, dimethylsulfoxide, and acetone. All reactions are preferably carried out at around room temperature, but depending on the type of reaction system, they may be carried out under heating if necessary. The lactone form of carboxylic acid having the formula () is
It is obtained by contacting the carboxylic acid obtained above with a catalytic amount of acid. The acid used is preferably an organic or mineral acid such as trifluoroacetic acid, hydrochloric acid, or sulfuric acid. The reaction is usually suitably carried out at around room temperature. Furthermore, the target compound thus obtained can be used as a raw material and converted into other target compounds according to the above-mentioned conventional chemical methods. The target compound thus obtained can be collected, separated, and purified by appropriately combining various methods. For example, this may be carried out by adsorption using various carriers such as activated carbon or silica gel, ion exchange chromatography, gel filtration using a Sephadex column, or extraction using an organic solvent such as ether, ethyl acetate, or chloroform. In particular, separation of isomers can be carried out by the above separation and purification means at an appropriate time after the completion of the conversion reaction or after the completion of the desired step. Examples will be shown next, but the present invention is not limited thereto. Example 1 3″-hydroxy-ML-236 lactone Glucose 20, Peptone 10, Yeast Extract 1.0
(g/) 500 containing 100ml of medium consisting of PH7.0
Four ml Erlenmeyer flasks were inoculated with Streptomyces sp. SANK62285 strain, and cultured with shaking (220 rpm) at 28°C for 48 hours. Obtained seed culture solution 150
ml was transferred to two 30-volume jar fermenters containing medium 15 with the same composition as above, and 0.01% of CB-442 was added as an antifoaming agent at an aeration rate of 15/min, an internal pressure of 1.0 Kg/cm 2 , and a stirring speed. 100~200r.pm culture temperature 28
The cells were cultured for 45 hours at ℃. ML−236 for this
Carboxylic acid sodium salt was added to the final concentration of 0.1%, and the culture was continued for an additional 50 hours. After the culture was completed, the culture solution was filtered to obtain a solution. Add liquid 26 for 2 15 jars to 2 HP-20 resin.
After adsorbing with SV4~5, wash with water (8),
Elution was carried out with a solvent of 30% acetone-water (33%) and 50% acetone-water (88%). 50% acetone-water elution fraction 8
was concentrated under reduced pressure to remove acetone. Concentrate 4.6
After adjusting the pH to 2.8-3.0 with 6N hydrochloric acid, the mixture was extracted with an equal amount of ethyl acetate (4x2). This ethyl acetate extract was washed with saturated brine (4x2), dried over anhydrous sodium sulfate, and concentrated to give 20g of oily concentrate.
I got it. 20 g of the obtained oily concentrate was dissolved in 100 ml of dry ethyl acetate, and trifluoroacetic acid was added to this.
0.5 ml was added and left to stand at 50°C for 3 hours to perform lactonization. Dilute the reaction solution with 400ml of ethyl acetate to 1%
After treatment with sodium bicarbonate solution, the mixture was washed with saturated brine and dried over anhydrous sodium sulfate. This ethyl acetate solution was concentrated (100 ml) and 12.8 g of precipitated crude crystals of 3″-hydroxy-ML-236B lactone were separated. A part of this crude crystal was purified by silica gel column chromatography (Si-60, n- The pure 3''-hydroxy-ML-236B lactone obtained by combining hexane-acetone (0 to 50 v/v%) exhibits the following physical constants. 1 Molecular formula: C 23 H 34 O 6 2 Molecular weight: 406 (SIMS mass spectrometry spectrum:
QM+H, 407) 3 Infrared absorption spectrum: ν nax cm -1 The infrared absorption spectrum measured in KBr is shown in FIG. 4 Carbon-13-nuclear magnetic resonance spectrum: δ: ppm The carbon-13-nuclear magnetic resonance spectrum (22.5 MHz) measured in deuterated chloroform using tetramethylsilane as an internal standard has the following chemical Kel shift (ppm ) and multiplicity. Chemikakel shift Multiplicity 1 10.9 Q 2 13.8 Q 3 20.0 Q 4 20.9 T 5 23.6 T 6 26.2 T 7 30.9 D 8 32.7 T 9 36.9 D 10 36.0 T 11 37.6 D 12 38.6 T 13 4 5.9 D 14 62.5 D 15 68.1 D 16 68.4 D 17 76.2 D 18 123.6 D 19 128.1 D 20 132.8 D 21 133.7 S 22 170.8 S 23 175.7 S Example 2 3″-hydroxy-ML-236B carboxylic acid sodium salt 3″-Hydroxy-ML- obtained in Example 1
2.0 g of 236B lactone was dissolved in 200 ml of methanol, and 50 ml of distilled water was added thereto. Add approximately equimolar amount of sodium hydroxide solution (0.25g/40ml) to this solution.
H2O ) was added dropwise at 40-50<0>C. During this time, the formation of sodium salt was confirmed by liquid chromatography. Approximately 2 hours after the dropwise addition, the reaction solution was adjusted to pH 8.5 with N-hydrochloric acid, concentrated under reduced pressure (50 ml) to remove methanol, and the aqueous layer was freeze-dried to give 3"-hydroxy-
2.6 g of ML-236B carboxylic acid sodium salt was obtained.
3″-Hydroxy-ML-236B carboxylic acid sodium salt exhibits the following physical constants: 1 Molecular formula: C 23 H 35 O 7 Na 2 Infrared absorption spectrum: ν nax cm -1 The infrared absorption spectrum measured in KBr is As shown in Figure 2. 3 Proton-nuclear magnetic resonance spectrum: δ: ppm The proton-nuclear magnetic resonance spectrum (270PH) measured in heavy water using tetramethylsilane as an internal standard is as shown in Figure 3. 4 Carbon-13-nuclear magnetic resonance spectrum: δ: ppm The carbon-13-nuclear magnetic resonance spectrum (22.5MHz) measured in heavy water using tetramethylsilane as an internal standard has the following chemical Kel shift. (ppm)
and multiplicity. Chemikakel shift Multiplicity 1 13.8 Q 2 14.7 Q 3 21.7 Q 4 21.9 D 5 25.2 T 6 27.0 D 7 31.8 D 8 35.5 T 9 38.2 T 10 38.3 T 11 44.6 T 12 45.6 T 13 4 8.6 D 14 68.8 D 15 69.4 D 16 70.0 D 17 71.1 D 18 124.0 D 19 129.0 D 20 134.5 D 21 135.0 S 22 177.7 S 23 180.9 S Example 3 Streptomyces sp.
Using SANK62385 strain and SANK62485 strain,
In the same manner as in Examples 1 and 2, 3''-hydroxy-ML-236B lactone and 3''-hydroxy-ML-236B carboxylic acid sodium salt were obtained. The physical constants were the same as those obtained in Examples 1 and 2. Test example Cholesterol synthesis inhibitory effect 3″-hydroxy-ML-236B consisting of a carboxylic acid having the above general formula (), a pharmacologically acceptable salt thereof, an ester thereof, or a closed ring lactone thereof
The derivative is 3-hydroxy-3-methylglutaryl coenzyme A reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase), which is known as the rate-limiting enzyme in the cholesterol synthesis pathway.
-3-methyl-glutaryl-Co A reductase)
was found to specifically inhibit Cholesterol synthesis inhibitory effect of these compounds [Journal of Biological Chemistry (J.Biol.
Chem.) Vol. 234, p. 2835 (1959)] are shown in Table 8.
【表】
トリウム塩
ML−236Bラクトン体(対照) 0.010
[Table] Thorium salt
ML-236B lactone (control) 0.010
Claims (1)
そのエステルまたはその閉環ラクトン体からなる
3″−ヒドロキシ−ML−236B誘導体。 2 式 を有するカルボン酸、その薬理上許容しうる塩、
そのエステルまたはその閉環ラクトン体からなる
ML−236B誘導体を、式 を有するカルボン酸、その薬理上許容しうる塩、
そのエステルまたはその閉環ラクトン体からなる
3″−ヒドロキシ−ML−236B誘導体に変換しうる
ストレプトミセス属に属する微生物を、ML−
236B誘導体を含有する培地で培養するか、ある
いはこの微生物の酵素抽出液とML−236B誘導体
とを接触せしめてML−236B誘導体を3″−ヒドロ
キシ−ML−236B誘導体に変換せしめ、変換反応
物を含む系より3″−ヒドロキシ−ML−236B誘導
体を採取することを特徴とする3″−ヒドロキシ−
ML−236B誘導体の製造法。[Claims] 1 formula a pharmacologically acceptable salt thereof,
Consists of its ester or its ring-closed lactone
3″-Hydroxy-ML-236B derivative. 2 Formula a pharmacologically acceptable salt thereof,
Consists of its ester or its ring-closed lactone
The ML-236B derivative has the formula a pharmacologically acceptable salt thereof,
Consists of its ester or its ring-closed lactone
A microorganism belonging to the genus Streptomyces that can be converted into a 3″-hydroxy-ML-236B derivative was
The ML-236B derivative is converted into a 3″-hydroxy-ML-236B derivative by culturing in a medium containing the 236B derivative, or by contacting the enzyme extract of this microorganism with the ML-236B derivative, and the conversion reaction product is converted into a 3″-hydroxy-ML-236B derivative. A 3″-hydroxy-ML-236B derivative is collected from a system containing the 3″-hydroxy-ML-236B derivative.
Method for producing ML-236B derivative.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20261485 | 1985-09-13 | ||
JP60-202614 | 1985-09-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS62174040A JPS62174040A (en) | 1987-07-30 |
JPH0366297B2 true JPH0366297B2 (en) | 1991-10-16 |
Family
ID=16460312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP20862086A Granted JPS62174040A (en) | 1985-09-13 | 1986-09-04 | 3"-hydroxy-ml-234b derivative and production thereof |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62174040A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997006142A1 (en) * | 1995-08-10 | 1997-02-20 | Nippon Soda Co., Ltd. | Pyridylmethylphenyl derivatives and process for production thereof |
JP2003012607A (en) * | 2001-06-26 | 2003-01-15 | Mercian Corp | Novel mevastatin derivative |
-
1986
- 1986-09-04 JP JP20862086A patent/JPS62174040A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS62174040A (en) | 1987-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0371116B2 (en) | ||
US4319039A (en) | Preparation of ammonium salt of hypocholesteremic fermentation product | |
US4342767A (en) | Hypocholesteremic fermentation products | |
JPH0371419B2 (en) | ||
JPH023623A (en) | Anti-hypercholesterolemia agent | |
EP0215665B1 (en) | Hydroxy-ml-236b derivatives, their preparation and use | |
JPH0115491B2 (en) | ||
JPH0366297B2 (en) | ||
JPH0354103B2 (en) | ||
US5272174A (en) | Hydroxy-ML-236B derivatives, their preparation and use | |
JPH0355471B2 (en) | ||
EP0381478A1 (en) | Process for the preparation of 6-alpha-hydroxymethyl lovastatin derivatives | |
JPH0482135B2 (en) | ||
JPH0333698B2 (en) | ||
JPH0724579B2 (en) | New microorganism | |
JP3067322B2 (en) | Method for producing 3'-hydroxybenanomycin A, an antifungal antibiotic | |
WO1992022660A1 (en) | Novel cholesterol lowering compound | |
JP2702764B2 (en) | Method for producing (7S) -cyclopenta [d] pyrimidine derivative | |
JPS6113798B2 (en) | ||
CA1340452C (en) | Novel hmg-coa reductase inhibitors | |
JP3327982B2 (en) | New antibiotic MI481-42F4-A related substance | |
EP0408806A1 (en) | Antihypercholesterolemic agents | |
JP2005000144A (en) | Streptomyces species cjpv 975652 which can convert compactin to pravastatin and method for producing pravastatin utilizing the same | |
JPS59179092A (en) | 3(2-substituted-oxazol-5-yl)indole, its salt and their preparation | |
JPH0525150A (en) | New decaloess tricutins and related compound, preparation thereof and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Cancellation because of no payment of annual fees |